⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954595 | 1.00 | — | — | |
| SCHEMBL2829059 | 0.79 | CES2 (0.38) | — | |
| SCHEMBL30050643 | 0.78 | CYP2A6 (0.31) | — | |
| SCHEMBL409191 | 0.78 | CYP2A6 (0.31) | — | |
| SCHEMBL8531624 | 0.76 | — | — | |
| SCHEMBL29954646 | 0.75 | ACHE (0.37) | — | |
| SCHEMBL1780996 | 0.72 | — | — | |
| SCHEMBL9844846 | 0.72 | — | — | |
| SCHEMBL29955606 | 0.71 | HDAC8 (0.38) | — | |
| SCHEMBL12415650 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230130739-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-04-27 | — | — | US | disclosed |
| EP-2978751-B1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
| US-20100321600-A1 | Display device | SHARP KABUSHIKI KAISHA (JP) | 2010-12-23 | — | — | US | disclosed |
| US-7768589-B2 | Display device | SHARP KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20100033663-A1 | Display device | SHARP KABUSHIKI KAISHA (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7639332-B2 | Display element and display device, driving method of display element, and program | SHARP KABUSHIKI KAISHA (JP) | 2009-12-29 | — | — | US | disclosed |
| US-7482344-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070088016-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070080370-A1 | Display device | SHARP KABUSHIKI KAISHA (JP) | 2007-04-12 | — | — | US | disclosed |
| WO-1999001456-A1 | SYNTHESIS OF AND INTERMEDIATES FOR CAMPTOTHECINS | UNIVERSITY OF PITTSBURGH (US) | 1999-01-14 | — | — | WO | disclosed |